AllDocs -> cancers

10th Anniversary Multiple Myeloma Research Foundation “Friends for Life” Fall Gala Saturday, October 28, 2006 Hyatt Regency – Greenwich, CT __Gala Benefactor $25,000 Name on all printed materials and signage, full-page ad in program book, verbal recognition during formal program, priority seating for a table of 10 (top seating with celebrity guests, MMRF Scientific Advisors and/or Board of Directors) Gala Sponsor $15,000 Name on all printed materials and signage, full-page ad in program book, verbal recognition during formal program, priority seating for a table of 10 (select seating with celebrity guests, MMRF Scientific Advisors and/or Board of Directors) Gala Patron $10,000 Name on all printed materials, half-page ad in program book, one table of 10 seats in prime location of ballroom (after Sponsors) Gala Partner $5,000 ...

The British Committee for Standards in Haematology Guidelines on the Diagnosis and Management of Multiple Myeloma 2005 British Journal of Haematology 2006;132:410-451 The guidelines can be found at www.bcshguidelines.com Serum Free Light Chain Assays THE BINDING SITE LIMITED P.O. Box 11712, Birmingham, B14 4ZB Tel: +44 (0)121 436 1000 Fax: +44 (0)121 430 7061 info@bindingsite.co.uk www.freelite.co.uk DTP196 March 06 The UK Myeloma Forum and the Nordic Myeloma Study Group have recently published their guidelines on the Diagnosis and Management of Multiple Myeloma . References to serum free light chain (FLC) analysis can be found in section 2: Diagnosis, investigations and indications for treatment. “Quantification of serum free immunoglobulin light chain levels and ?/? ratio can be used as an alternative to ...

Page 2 page 1 It is a disease that starts in the marrow. The marrow – the spongy tissue found in the center of the bone – is the part of the body that makes red and white blood cells. In myeloma , one type of developing white blood cell (B lymphocyte), called a plasma cell, grows continuously to form a mass, or tumor, in the marrow. • When there are too many plasma cells, they crowd out developing, normal white and red blood cells. • The plasma cells in myeloma make factors that cause bone to dissolve, leading to fractures. • Fewer red blood cells result in less oxygen being carried to the tissue throughout the body, causing fatigue and shortness of breath with exercise. • Fewer white blood cells make it harder to fight infection. Myeloma is a type of cancer This booklet is designed to provide information in regard to the subject matter covered. ...

Don Baylor Former MLB All-Star, AL MVP and Multiple Myeloma Survivor Former MLB All-Star, AL MVP and multiple myeloma survivor Don Baylor is a new member of the Strike Out Cancer team. As a cancer survivor, family caregiver, and a former player, manager and coach, Baylor knows the benefits of a team approach both on and off the field. He encourages all cancer patients to build their own team of healthcare professionals, support services and loved ones. Born in Austin, Texas, Baylor was drafted in the 2nd round of the 1967 amateur draft by Baltimore. Baylor was known for crowding the plate, and set a new major league career record for being hit by pitches in 1987 (breaking Ron Hunt's modern-day record of 243), finishing his career with 267. That record stood until it was broken in 2005. During his 19-year playing career, Baylor was a power hitter who played for six American League teams: the Baltimore Orioles, ...

Volume VII Issue I SPRING 2006 Accelerating the Search for a Cure INSIDE THIS ISSUE M U L T I P L E MY E L O M A RESEARCH FOUNDATION MYELOMA FOCUS Newsletter of the MMRF Scientific Agenda Pages 2 - 3 MMRC Pages 4 - 5 Translational Research Page 6 Update from ASH Pages 7 - 9 You Need To Know Page 10 - 11 Industry Update Page 12 Families Funding Research Page 13 Fundraising Pages 14 - 17 Leadership Council Page 18 MMRF/MMRC Welcomes New President Page 19 Honorary Board Page 20 nce again the MMRF is proud to be recognized by Charity Navigator, America’s largest independent evaluator of charitable organizations, for our exceptional fiscal management and clear commitment to our ...

. . . . . . . . . . . . Contact: François Houÿez EURORDIS Telephone 00 33 1 56 53 52 18 Plateforme Maladies Rares 102 rue Didot 75014 Paris Tel.: 00 33 1 56 53 52 18 francois.houyez@eurordis.org Press release Thalidomide: patients denounce the withdrawal of the marketing authorisation application for multiple myeloma treatment. Multiple myeloma patients’ representatives opposed to Pharmion Corporation’s decision. EMEA/patients dialogue still inadequate. Paris, June 8 th 2004: Despite its dramatic history, thalidomide should now be evaluated exactly on the same basis as other medicinal products. Facts from 1957- 1962 should not obliterate scientific data and medical needs in 2004. ° Patients with multiple myeloma and their organisations ...

FEEDBACK PROJECT FOCUSES ON PATIENTS’ NEEDS (continued on page 4) (continued on page 3) The Myeloma Institute for Research and Therapy launched the Patient Initiated Quality Improvement Project in January. The pilot program is designed to improve the quality of clinical care and customer service at the center. The six-month project, funded by a grant from the Cynthia and George Mitchell Foundation, involves the analysis of detailed patient feedback by a committee comprised of University of Arkansas for Medical Sciences staff and Myeloma Institute patients. A total of twelve patients are providing the committee with elec- tronic feedback regarding their clinical experiences and other aspects of treatment via e-mail, according to Dr. Elias Anaissie, the Myeloma Institute’s director of the Supportive Care Division. “We’ve encouraged ...

184 www.blackwellpublishing.com/journals/afm LETTER TO THE EDITOR Asia Pacific Family Medicine 2003; 2 : 184 Blackwell Science, LtdOxford, UKAFMAsia Pacific Family Medicine1444-1683© 2003 Blackwell Publishing Asia Pty LtdSeptember 200223184Letter to the EditorLetter to the EditorLetter to the Editor Accepted for publication 7 June 2003. LETER TO THE EDITOR Atypical presentation of myeloma General Practice is fascinating because of the variety of cases and the wealth of clinical material that a Family Physician is in a fortunate position to see and help. Doctors working in very few specialties have first hand access to such a vast array of clinical cases in this era of specialization. This unique position of Family Physi- cians has its advantages and disadvantages. The disad- vantage is that it is obligatory in order to be a good Family Physician ...

HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo * Received for publication,July 25, 2005, and in revised form, September 15, 2005 Published, JBC Papers in Press,September 27, 2005, DOI 10.1074/jbc.M508136200 Yuemeng Dai ‡ , Yang Yang ‡ , Veronica MacLeod ‡ , Xinping Yue § , Alan C. Rapraeger § , Zachary Shriver ¶ , Ganesh Venkataraman ¶ , Ram Sasisekharan , and Ralph D. Sanderson ‡1 From the ‡ Department of Pathology and the Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, the § Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53706, ¶ Momenta Pharmaceuticals, Inc., Cambridge, ...

Comparative Data Mining for Microarrays: A Case Study Based on Multiple Myeloma David Page * Dept. of Biostatistics and Medical Informatics & Dept. of Computer Sciences University of Wisconsin Madison, WI 53706 Fenghuang Zhan Lambert Laboratory of Myeloma Genetics University of Arkansas for Medical Sciences Little Rock, AR 72205 James Cussens Computer Science Dept. University of York Heslington York YO10 5DD United Kingdom Michael Waddell Dept. of Computer Sciences & Dept. of Biostatistics and Medical Informatics University of Wisconsin Madison, WI 53706 Johanna Hardin Southwest Oncology Group Fred Hutchinson Cancer Research Center Seattle, WA 98109 Bart Barlogie Myeloma Institute for Research and Therapy University of Arkansas ...

Living Successfully with Multiple Myeloma By Peter Tischler North Texas Myeloma Support Group by Peter Tischler I’m not the smartest guy around and, to be honest, I’d guess that many people in our group are smarter than me. But I’m very good at one thing: I can absorb an enormous amount of data, condense it into a summary, and communicate the results of that data to other people in such a way that they will understand it. That’s what I did in business and that’s what I’ve been doing with information about myeloma . Mostly, I do this one-on-one when people ask for help. This editorial is an attempt to reach a larger audience of people with our disease. When I was diagnosed with multiple myeloma (MM) and was led to believe that I would only be around for a few years, I thought about what I wanted from medical science. I decided that I wanted quality of life and a chance to ...

Last revised 10/27/2005 UM Cancer Center Patient Education Document #0046 Nov05 Ed. Online version at: http://www.cancer.med.umich.edu/learn/pwadultsarcoma.htm 1 University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Multiple Myeloma The purpose of this information guide is to help patients newly diagnosed with Multiple Myeloma find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center of the University of Michigan Comprehensive Cancer Center, in room B1-361. Brochures Available free in the Patient Education Resource Center on level B-1 The Leukemia & Lymphoma Society. Myeloma Full-text available online ...

Understanding Caring for people with cancer myeloma Page 2 This booklet has been written to help you understand more about myeloma . It has been prepared and checked by doctors, other relevant specialists, nurses and patients. The information in this booklet is an agreed view on myeloma , how it is treated and how treatment may affect you. If you are a patient, your doctor or nurse may go through the booklet with you and mark sections that are important for you. You can also make a note below of the contact names and information that you may need quickly. . myeloma Understanding Specialist nurse/contact names Hospital Tel Emergency Tel Treatments Family doctor Surgery address Tel Review dates If you like, you can also add: Your name Address Page ...

Original Article Improved Survival in Patients with Multiple Myeloma Treated with DMVM plus IFN- Teruo Kitani, Yukihiro Tokumine, Tohru Masaoka, Atsushi Horiuchi, Eizo Kakishita, Takashi Kageyama, Noriyuki Tatsumi, Jun Kuyama, Kunio Hayashi, Machiko Tsukaguchi, Hiroya Kawagoe, Hedeki Fujitake, Tadahiro Tsubakio, Kaori Nasu, Yoshiteru Konaka, Tsuyoshi Yonezawa and Kiyoyasu Nagai. for the Hanshin Study Group on Treatment for Hematological Disorders We examined effects of combination chemotherapy with dexamethasone, melphalan, vincristine, and MCNU (DMVM), plus IFN- in patients with previously untreated and treated multiple myeloma (MM).In the study, 78 previously untreated and 47 treated MM patients were evaluated.The overall response rate was 76% [27% complete response (CR)] : 85% [37% CR] in previously untreated patients and 62% [11% CR] in previously treated patients.The 50% survival time was ...

—more— Embargoed for Release: Monday, Nov. 14, 2005 12 pm noon EST Contact: Teresa Herbert, Richard Saltus 617-632-5653 Compound from marine bacteria shows potential as multiple myeloma therapy Kills blood cancer cells with low toxicity in preclinical studies BOSTON—An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell . The experimental compound, NPI-0052, has been found to block or inhibit cancer cells’ proteasomes from working effectively. The proteasome work as a cell’s “garbage disposal,” chewing up and disposing of old, unwanted proteins. With their proteasome jammed, cells die from the backup of damaged proteins. ...

8 7 Copyright © 2001 by The Indian Society of Nephrology Indian J Nephrol 2001;11: 87 LETTER TO THE EDITOR Acute myeloma kidney 5 8 years old male presented with the history of swelling of feet, puffiness of face and diminished urine output following strenuous road journey in hot and humid weather and consumption of 6 tablets of voveran for backache. Investigation revealed raised ESR (155 mm) and anemia (Hb 7.5gms%). Bence-Jones proteinuria and lytic bone lesions were not detected. Blood urea and serum creatinine were 210 and 12.5 mg% respectively. Serum calcium was 7.5 mg%. Immunofixation electrophoresis revealed positive band in IgA and kappa region. With a diagnosis of IgA multiple myeloma with acute renal failure, he was started on twice weekly hemodialysis and monthly pulse chemotherapy consisting of melphalan and prednisolone. A kidney biopsy ...

6 6 Copyright © 2001 by The Indian Society of Nephrology Indian Journal of Nephrology Indian J Nephrol 2001;11: 66-67 CASEREPORT Multiple Myeloma : A rare malignancy in the post transplant period RK Gundappa, K Sud, HS Kohli, V Jha, KL Gupta, V Sakhuja Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh. Address for Correspondence: Prof. V. Sakhuja, Head, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160012 email: vsakhuja@glide.net.in Introduction An increased incidence of neoplasia is a well recognized complication of long term immunosuppressive therapy. Renal transplant recipients are therefore at increased risk of developing this complication. The prevalence of neoplasia is reportedly 14% in first 10 years and increases to 40% ...

Mayo Clin Proc. • December 2005;80(12):1549-1551 • www.mayoclinicproceedings.com 1549 EDITORIAL Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma EDITORIAL This work was supported in part by grants CA62242, CA85818, CA93842, and CA100080 from the National Cancer Institute. Dr Rajkumar has received research support from Celgene Corp and Millennium Pharmaceuticals to conduct clinical trials at the Mayo Clinic. Address correspondence to S. Vincent Rajkumar, MD, Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905 (e- mail: rajks@mayo.edu). © 2005 Mayo Foundation for Medical Education and Research See also page 1568 T he treatment of multiple myeloma (MM) has under- gone radical changes in recent years with the arrival of active agents such as thalidomide and bortezomib. 1-4 ...

MYELOMA MANAGEMENT GUIDELINES A CONSENSUS REPORT FROM THE SCIENTIFIC ADVISORS OF THE INTERNATIONAL MYELOMA FOUNDATION Brian G.M. Durie, Robert Kyle, Andrew Belch, William Bensinger, Joan Blade, Mario Boccadoro, J. Anthony Child, Raymond Comenzo, Dorotea Fantl, Gosta Gahrton, Jean Luc Harousseau, Vania Hungria, Douglas Joshua, Heinz Ludwig, Jayesh Mehta, Angelina Morales, Gareth Morgan, Amara Nouel, Martin Oken, Raymond Powles, David Roodman, Jesus San Miguel, Kazuyuki Shimizu, Seema Singhal, Bhawna Sirohi, Pieter Sonneveld, Guido Tricot, Brian Van Ness, Ben Djulbegovic. Corresponding Author: Brian G.M. Durie bdurie@salick.com T: 323-966-3572 F: 323-966-3685 Running title: MYELOMA MANAGEMENT GUIDELINES Consultants & Others Present : Philip Greipp, Robert Knight, Sean Maenpaa, Susie Novis, Lisa Paik, Michael Rosenzweig, Iain Webb. ...

Corporate Medical Policy Bone Marrow Transplant for Multiple Myeloma File Name: bone_marrow_transplant_for_multiple_myeloma Policy Number: SUR6090.14 Origination: 2/2001 Last Review: 11/2004 Next Review: 11/2006 Description of Procedure or Service This policy addresses high-dose chemotherapy with hematopoietic s tem-cell support as a treatment of mul- tiple myeloma . Bone marrow transplants typically include high-dose chemotherapy (HDC). "High-dose chemotherapy" (HDC) involves the administration of cytotoxic agents for the treatment of can- cer. It uses doses several times greater than the standard therapeutic dose. In some cases, whole body or localized radiotherapy is also given and is included in the term HDC. The rationale for HDC is that many cytotoxic agents act according to a steep dose-response curve . Thus, small increments ...

CONTACTS: International Myeloma Foundation Media Los Angeles Media Candace MacDonald Stephen Gendel Peggy Frank 818-487-7455 212-918-4650 818-735-3591 THE INTERNATIONAL MYELOMA FOUNDATION HONORS DR. DAVID AGUS FOR USE OF WORLD’S MOST POWERFUL MAGNETS TO UNLOCK SECRETS OF CANCER TREATMENT -- NOV. 12, BEVERLY HILTON - Dr. Agus’ Research Helps Determine Which Patients Respond Best to Specific Treatments – --15th Annual Ribbon of Hope Gala to Pay Him Tribute-- North Hollywood, CA, October 20, 2005 -- The International Myeloma Foundation - conducting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today announced it is singling out for honors David B. Agus, M.D., a nationally prominent researcher at Cedars-Sinai Medical Center in Los Angeles, for his cutting edge research ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 11 October 2005 Doc.Ref.: EMEA/COMP/262/2004 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF thalidomide for the treatment of multiple myeloma On 19 December 2001, orphan designation (EU/3/01/068) was granted by the European Commission to Kendle International Limited, United Kingdom, for thalidomide for the treatment of multiple myeloma . What is multiple myeloma ? Multiple myeloma is a cancer of a type ...

What You Need To Know About Multiple Myeloma U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute ™ What You Need To Know About Index Page 2 This booklet is about multiple myeloma . The Cancer Information Service can help you learn more about this disease. The staff can talk with you in English or Spanish. The number is 1–800–4–CANCER (1–800–422–6237). The number for callers with TTY equipment is 1–800–332–8615. Your call is free. Este folleto es acerca del mieloma múltiple. Llame al Servicio de Información sobre el Cáncer para saber más sobre esta enfermedad. Este servicio tiene personal que habla español. El número a llamar es el 1–800–4–CANCER (1–800–422–6237). Personas con ...

2005 estimate 2004 2000 2001 2003 2002 Fiscal Year Millions of Dollar s 0 i 5 10 15 20 30 25 $26.3M $18.0M $19.7M $20.8M $23.9M $24.2M Incidence and Mortality Rate Trends Myeloma , also known as multiple myeloma or plasma cell myeloma , is the second most common blood cancer in the United States and comprises approximately 1 percent of all cancers. Unfortunately, there has been little change in the overall incidence rate of myeloma , and the mortality rate has increased over the past three decades. The incidence rate is higher in men than women. Myeloma is more common among the elderly, and African Americans have approximately double the incidence and mortality rates of Whites. Source for ...

CASE REPORT Multiple Myeloma Involving the Cricoid Cartilage Giorgio Peretti, MD, Cesare Piazza, MD, Loredana Provenzano, MD, Marco Giudice, MD, Brescia, Italy M ultiple myeloma (MM) is 1 of the 3 clinical entities in which plasma cell dyscrasias may appear in the head and neck. The other 2 forms are represented by extramed- ullary (EMP) and solitary bone plasmacytomas (SBP). Such types of plasma cell lesions are histologically indistinguish- able from each other, thus representing distinct manifesta- tions of a continuous pathologic spectrum. 1 Therefore, an appropriate differential diagnosis rests solely on clinical findings. In particular, MM localized to the larynx is defined as a plasma cell tumor that involves the marrow space formed after osseous metaplasia of the laryngeal cartilages occurring in the elderly, associated with signs of systemic ...

Nonsecretory Multiple Myeloma Nonsecretory Multiple m Multiple Nonsecretor Multiple Myeloma Nonsecretory Multipl Myeloma Nonsecretory Multiple m Freelite serum free light chains can be identified in 82% of NSMM patients Freelite enables sensitive quantification of serum free light chains for diagnosis and monitoring. Nonsecretory Multiple Myeloma Freelite TM Serum Free Light Chain Assay Page 2 Freelite serum free light chains can be identified in 82% of NSMM patients. Freelite enables sensitive quantification of serum free light chains for diagnosis and monitoring. Accuracy of different diagnostic approaches for monoclonal proteins Using data currently available 1-4 , Table 1 shows ...

National Cancer Institute SEER Program 88 MULTIPLE MYELOMA M ultiple myeloma , sometimes called plasma cell myeloma , arises in bone marrow and involves the plasma cells, a type of blood cell that normally plays a crucial role in the immune response by producing antibodies. It is classified as a lymphoproliferative disease and is therefore related to the lymphomas. In some early classification schemes, multiple myelomas were included in statistics on lymphomas. There is considerable variation in the incidence of the disease. Among men, age- adjusted incidence rates (per 100,000) range from a low of 1.6 among Japanese to a high of 11.3 among blacks, a seven-fold difference. This difference is particularly interesting since the opposite relationship holds for Ewing’s sarcoma, a type of bone tumor that is extremely rare among ...